142 related articles for article (PubMed ID: 6354731)
1. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
[TBL] [Abstract][Full Text] [Related]
2. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
Schwandt P; Weisweiler P; Neureuther G; Wilkening J
MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
[TBL] [Abstract][Full Text] [Related]
3. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
Enger SC; Johnsen V; Samuelsen A; Laws EA
Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
[TBL] [Abstract][Full Text] [Related]
4. [Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia. Behavior of plasma lipids, glucose tolerance, and plasma insulin after glucose load during treatment with clofibrate].
Bruns W; Rjasanowski I; Wulfert P; Michael R; Knospe S; Hildmann W
Endokrinologie; 1974 Nov; 64(1):2-12. PubMed ID: 4466653
[No Abstract] [Full Text] [Related]
5. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
[TBL] [Abstract][Full Text] [Related]
6. Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol.
Lithell H; Vessby B; Hellsing K
Atherosclerosis; 1982 Jun; 43(2-3):177-84. PubMed ID: 7052096
[TBL] [Abstract][Full Text] [Related]
7. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
[TBL] [Abstract][Full Text] [Related]
8. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
[TBL] [Abstract][Full Text] [Related]
9. The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies.
Lithell H; Vessby B; Boberg J; Hellsing K
Atherosclerosis; 1980 Oct; 37(2):175-86. PubMed ID: 7000089
[TBL] [Abstract][Full Text] [Related]
10. [Effect of glibenclamide therapy on carbohydrate and lipid metabolism and insulin secretion in patients with glucose tolerance disorders : a 5-year study].
Ratzmann KP; Witt S; Schulz B; Jahr D; Heinke P
Z Gesamte Inn Med; 1981 Dec; 36(23):913-7. PubMed ID: 6805141
[TBL] [Abstract][Full Text] [Related]
11. The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance.
Ratzmann KP; Witt S; Schulz B
Diabete Metab; 1983; 9(2):87-93. PubMed ID: 6413265
[TBL] [Abstract][Full Text] [Related]
12. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
[No Abstract] [Full Text] [Related]
13. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.
Kobayashi M; Shigeta Y; Hirata Y; Omori Y; Sakamoto N; Nambu S; Baba S
Diabetes Care; 1988 Jun; 11(6):495-9. PubMed ID: 3042317
[TBL] [Abstract][Full Text] [Related]
14. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
[TBL] [Abstract][Full Text] [Related]
15. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus.
Ferrari C; Romussi M; Bertazzoni A; Testori GP; Grimaldi MG
Biomedicine; 1978 Jun; 29(4):133-6. PubMed ID: 556385
[TBL] [Abstract][Full Text] [Related]
16. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes.
Ferrari C; Testori GP; Bertazzoni A; Romussi M; Caldara R; Frezzati S
Horm Metab Res; 1978 Jan; 10(1):4-6. PubMed ID: 631736
[TBL] [Abstract][Full Text] [Related]
17. [The effect of insulin on hyperlipoproteinemia induced by a semi-synthetic diet rich in saturated fats in a rabbit].
Lacombe C; Nibbelink M
Diabete Metab; 1983 Mar; 9(1):35-41. PubMed ID: 6343152
[TBL] [Abstract][Full Text] [Related]
18. [Effect of clofibrate therapy on the glucagon and insulin secretion as well as on the glucose tolerance in patients with type IV hyperlipoproteinemia].
Drost H; Grüneklee D; Korthaus G; Gries FA
Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():835-8. PubMed ID: 1029295
[No Abstract] [Full Text] [Related]
19. [Clofibrate treatment of hyperlipoproteinemia].
Oikawa S; Midorikawa H
Nihon Rinsho; 1994 Dec; 52(12):3285-91. PubMed ID: 7853724
[TBL] [Abstract][Full Text] [Related]
20. [Effect of clofibrate on glucide tolerance in patients with ischemic heart disease and hyperlipoproteinemia].
Bornemisza P; Csögör I
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1978; 30(6):543-6. PubMed ID: 34860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
